Literature DB >> 12534871

Guillain-Barré syndrome and hyponatraemia.

B M Colls1.   

Abstract

BACKGROUND: Hyponatraemia is a recognized association of the Guillain-Barré syndrome (GBS) and is also known to occur after the administration of intravenous infusion of gamma globulin (IVIG), a treatment often used in management of GBS. AIMS: To document serum sodium concentration in GBS patients before, during and after management procedures (including IVIG) positive pressure ventilation (PPV) and the use of medications capable of causing a low serum sodium. To consider whether pseudohyponatraemia might be a contributory factor. To assess whether hyponatraemia is a predictor of poor outcome.
METHODS: Clinical record audit of 84 patients with GBS admitted to Christchurch Hospital, New Zealand, over a 10-year period.
RESULTS: Serum sodium concentration was significantly low (<133 mmol/L) in 26 of 84 (31%) patients. In 12 of these cases the hyponatraemia developed during or after IVIG, suggesting that pseudo-hyponatraemia was a contributing factor. Six (7%) significantly hyponatraemic patients died, but no eunatraemic or slightly hyponatraemic patient died (P = 0.001). Six of 38 patients aged > or =50 years died, whereas none of the 46 patients aged <50 years died (P = 0.007). Five of 19 ventilated patients died but only one of 65 non-ventilated died (P = 0.002).
CONCLUSIONS: Significant hyponatraemia occurred in 26 (31%) of the patients, but in 12 of these it appeared likely that pseudohyponatraemia caused by IVIG was a contributing factor. Hyponatraemic patients have a poorer prognosis than eunatraemic patients, however it is difficult to separate this factor from other poor prognostic factors (older age and PPV).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12534871     DOI: 10.1046/j.1445-5994.2002.00322.x

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  10 in total

1.  SIADH in a patient with sensory ataxic neuropathy with anti-disialosyl antibodies (CANOMAD).

Authors:  Raffaele Iorio; Fioravante Capone; Elisabetta Iannaccone; Hugh John Willison; Anna Modoni; Pietro Attilio Tonali; Gabriella Silvestri
Journal:  J Neurol       Date:  2009-03-01       Impact factor: 4.849

2.  Pseudohyponatremia: does it matter in current clinical practice?

Authors:  Gheun-Ho Kim
Journal:  Electrolyte Blood Press       Date:  2006-11

3.  [Guillain-Barrè syndrome and inadequate antidiuretic hormone secretion syndrome].

Authors:  P Pöschl; Z Kohl; U Thoden; J Winkler; W Jakob
Journal:  Nervenarzt       Date:  2006-12       Impact factor: 1.214

4.  Dysautonomia and hyponatraemia as harbingers of Guillain-Barre syndrome.

Authors:  Preet Mukesh Shah; Vijay Waman Dhakre; Ramya Veerasuri; Anand Bhabhor
Journal:  BMJ Case Rep       Date:  2019-04-15

5.  Prognostic factors of Guillain-Barré syndrome: a 111-case retrospective review.

Authors:  Yitao Zhang; Yanyin Zhao; Yi Wang
Journal:  Chin Neurosurg J       Date:  2018-06-18

Review 6.  Hyponatremia in hospitalized critically ill children: current concepts.

Authors:  Sunit Singhi
Journal:  Indian J Pediatr       Date:  2004-09       Impact factor: 1.967

7.  True hyponatremia secondary to intravenous immunoglobulin.

Authors:  Minhtri K Nguyen; Anjay Rastogi; Ira Kurtz
Journal:  Clin Exp Nephrol       Date:  2006-06       Impact factor: 2.617

8.  Acute renal failure, severe sodium and potassium imbalance and sudden tetraplegia.

Authors:  Giorgina Barbara Piccoli; Marco Capobianco; Lorenzo Odetto; Maria Chiara Deagostini; Valentina Consiglio; Giulio Radeschi
Journal:  NDT Plus       Date:  2010-03-19

9.  Severe hyponatremia as the initial sign preceding guillain-barré syndrome, an acute inflammatory demyelinating polyneuropathy: a case report.

Authors:  Benjamin Kloesel; Latonya J Hickson
Journal:  Case Rep Neurol Med       Date:  2013-02-05

Review 10.  Inappropriate Antidiuretic Hormone Secretion and Cerebral Salt-Wasting Syndromes in Neurological Patients.

Authors:  Haiying Cui; Guangyu He; Shuo Yang; You Lv; Zongmiao Jiang; Xiaokun Gang; Guixia Wang
Journal:  Front Neurosci       Date:  2019-11-08       Impact factor: 4.677

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.